A patent from Centre National de la Recherche Scientifique (CNRS), McGill University and Sorbonne University discloses new acetylcholinesterase (AChE) inhibitors reported to be useful for the treatment of substance abuse and dependence, obsessive-compulsive disorder, anorexia nervosa, bulimia nervosa, obesity, Parkinson’s and Alzheimer’s disease.

Work at Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. has led to the discovery of new protein arginine N-methyltransferase 5 (PRMT5) inhibitors reported to be useful for the treatment of cancer.

Daegu-Gyeongbuk Medical Innovation Foundation and Provibio Co. Ltd. have identified new compounds described as potentially useful for the treatment of cancer and autoimmune diseases.

Cincinnati Children’s Hospital Medical Center, Kurome Therapeutics Inc. and the U.S. Department of Health and Human Services have jointly patented interleukin-1 receptor-associated kinase 1 (IRAK-1) and/or IRAK-4 and/or FLT3 (FLK2/STK1) inhibitors reported to be useful for the treatment of cancer, autoimmune and inflammatory disorders.

The Institute of Physical and Chemical Research, the National Institute of Infectious Diseases Japan and Shizuoka Prefectural University have discovered prodrugs of furanocoumarin derivatives acting as dihydroorotate dehydrogenase (DHODH) inhibitors and reported to be useful for the treatment of viral infection.

Copper complexes acting angiogenesis inhibitors have been disclosed in a patent from Istinye Universitesi and Karadeniz Teknik Universitesi Teknoloji Transferi Uygulama ve Arastirma Merkezi as potentially useful for the treatment of cancer.

Work at DE Shaw Research LLC has led to the identification of bicyclic imide compounds acting as transient receptor potential cation channel subfamily A member 1 (TRPA1) antagonists.

Recent Beigene Ltd. patents describe condensed heterocyclic compounds acting as diacylglycerol kinase α (DGK-α) and/or DGK-ζ (DGK-ζ) inhibitors and reported to be useful for the treatment of cancer.

Eurofarma Laboratórios SA and Universidade Federal do Rio de Janeiro (UFRJ) have jointly patented new sodium channel protein type 9 subunit α (SCN9A; Nav1.7) and/or SCN10A (Nav1.8) blockers reported to be useful for the treatment of pain.

Zymedi Co. Ltd. has patented compounds acting as lysyl tRNA synthetase (KARS) inhibitors and reported to be useful for the treatment of cancer metastasis, inflammation, fibrosis and cardiovascular disorders.